维普期刊资源整合服务平台（V6.5）

73篇 您的检索式：作者名="WIGLER N"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Cloning the differences between two complex genomes 显示文摘	Lisitsyn N Wigler M	1993	Science1993，259，5097：	1
2	Cloning the differences between two coplex genomes 显示文摘	Lisitsyn N Wigler M	1993	Science1993，259，：	1
3	Monthly gemcitabine(days 1,8and15) plus cisplatin (days 1-3) in advanced nonsmall-cell lung cancer: a phase Ⅱ study显示文摘	Merimsky D Wigler N Greif Y etal	2000	Anticancer Drugs2000，11，2：	1
4	Reduced cardiotoxicity and comparable efficacy in a phase Ⅲ trial of pegylated liposomal doxorubicin HC1 (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer显示文摘	O'Brien ME Wigler N lnbar M	2004	Ann Oncol2004，15，3：	1
5	Cloning the differences be- tween two complex genomes显示文摘	Lisitsyn N Lisitsyn N Wigler M	1993	Science1993，259，：	1
6	Monthly gemcitabine (days 1,8 and 15)plus cisplatin (days 1-3)in advanced non-small cell lung cancer:a phase Ⅱ study显示文摘	Merimsky O Wigler N Greif Y	2000	Antiancer Drugs2000，11，2：	1
7	Cloning the differences between two complex genomes显示文摘	Lisitsyn N Lisitsyn N Wigler M	1993	Science1993，259，：	1
8	Cisplatin-related Lher-mitte's sign显示文摘	Inbar M Merimsky O Wigler N	1992	Anticancer Drugs1992，3，4：	1
9	Monthly gemcitabine (days 1, 8 and 15) plus cisplatin (days 1-3) in advanced non-small-cell lung cancer: a phase Ⅱ study显示文摘	Wigler N Greif Y	2000	Anticancer Drugs2000，11，2：	1
10	Cloning the differences between two complex genomes显示文摘	Lisitsyn N Lisitsyn N Wigler M	1993	Science1993，259，5097：	1
11	Reduced cardiotoxicity and comparable efficacy in a phase HI trial of pegylated liposo- mal doxorubicin HCI (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer显示文摘	O' Brien ME Wigler N Inbar M	2004	Ann Oncol2004，15，3：	1
12	Cloning the differences between two complex genomes 显示文摘	WIGLER M	1993	Science1993，259，12：	1
13	Reduced cardiotoxicity and comparable efficacy in a phase Ⅲ trial of pegylated liposomal doxorubicin HCL(Caelyxtm/Doxil )versus conventional doxorubicin for first-line treatment of metastatic breast cancer显示文摘	O'brien ME Wigler N Inbar M	2004	Ann Oncol2004，15，3：	1
14	Monthly gemcitabine(days 1,8 and 15)plus cisplatin (days 1-3)in advance non-small cell cancer:a phase Ⅱ study显示文摘	Wigler N Greif Y	2000	Anticancer Drugs2000，11，2：	1
15	Cloning the differences between two complex genomes显示文摘	WIGLER M	1993	Science1993，259，：	1
16	Cloning the differences between two complex genomes显示文摘	LISITSYN N WIGLER M	1993	Science1993，259，：	1
17	Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HC1 (CAELYXTM/Doxil(R)) versus conventional doxorubicin for firstline treatment of metastatic breast cancer显示文摘	O' Brien M E Wigler N Inbar M	2004	Ann Oncol2004，15，3：	1
18	Cloning the differences between two complex genomes 显示文摘	Lisitsyn N Wigler M	1993	Science1993，259，5097：	1
19	Monthly gemcitabine(days 1,8 and 15)plus cisplatin (days 1-3)in advanced non-small cell lung cancer:a phase Ⅱ study显示文摘	Morimsky O Wigler N Greif Y	2000	Antiancer Drugs2000，11，2：	1
20	Cloning the differences between two com- plex genomes显示文摘	Lisitsyn N Wigler M	1993	Science1993，259，：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示